Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 211650
Company: APOTEX

Products on ANDA 211650

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
AXITINIB	AXITINIB	1MG	TABLET;ORAL	Prescription	AB	No	No
AXITINIB	AXITINIB	5MG	TABLET;ORAL	Prescription	AB	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 211650

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
10/30/2025	ORIG-1	Approval		STANDARD	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211650Orig1s000TA_ltr.pdf

Therapeutic Equivalents for ANDA 211650

AXITINIB

TABLET;ORAL; 1MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
AXITINIB	AXITINIB	1MG	TABLET;ORAL	Prescription	No	AB	211650	APOTEX
INLYTA	AXITINIB	1MG	TABLET;ORAL	Prescription	Yes	AB	202324	PF PRISM CV

TABLET;ORAL; 5MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
AXITINIB	AXITINIB	5MG	TABLET;ORAL	Prescription	No	AB	211650	APOTEX
INLYTA	AXITINIB	5MG	TABLET;ORAL	Prescription	Yes	AB	202324	PF PRISM CV